Context Urologists regularly develop clinical risk prediction models to support clinical
decisions. In contrast to traditional performance measures, decision curve analysis (DCA) …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …

Over the last decades, transcriptome profiling emerged as one of the most powerful
approaches in oncology, providing prognostic and predictive utility for cancer management …

The development of more specific biomarkers for prostate cancer and/or high‐risk prostate
cancer is necessary, because the prostate‐specific antigen test lacks specificity for the …

Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of
cancer-related death. Early detection of prostate cancer is largely determined by a widely …

Context Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid
since the introduction of new technologies such as risk calculators (RCs) and magnetic …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Early detection of prostate cancer (PC) is largely carried out using assessment of prostate-
specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies …